Tags

Type your tag names separated by a space and hit enter

Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Gynecol Endocrinol. 2016; 32(1):42-5.GE

Abstract

The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS). Thirty-seven patients with PCOS were randomly assigned to receive spironolactone 100 mg/d (spironolactone group, 18 patients) or spironolactone 100 mg/d plus metformin 2000 mg/d (combination group, 19 patients) for 12 months. BMI, modified Ferriman-Gallway score (FGS), serum levels of regarding hormones, and homeostasis model assessment of insulin resistance (HOMA-IR) index were assessed before and after the treatments. Six patients in the spironolactone group and four patients in the combination group reported inter-menstrual vaginal bleeding during treatments. In hirsutism scores, the spironolactone therapy resulted in 25.2% reduction, while combination therapy resulted in 28.3% reduction (p > 0.05, between groups). When the groups were compared in terms of percent changes in BMI, FGS, HOMA-IR, and hormone values other than free testosterone, no significant difference was noted. In the present study, FGSs were significantly decreased in both groups; however, combination therapy was not more effective than spironolactone alone in terms of BMI, FGS, hormone levels, or insulin resistance.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Diri H
a Division of Endocrinology and.
Karaburgu S
a Division of Endocrinology and.
Acmaz B
b Department of Internal Diseases , Erciyes University Medical School , Kayseri , Turkey.
Unluhizarci K
a Division of Endocrinology and.
Tanriverdi F
a Division of Endocrinology and.
Karaca Z
a Division of Endocrinology and.
Kelestimur F
a Division of Endocrinology and.

MeSH

AdolescentAdultBlood GlucoseBody Mass IndexDehydroepiandrosterone SulfateDrug Therapy, CombinationEstradiolFemaleFollicle Stimulating HormoneHirsutismHumansHydrocortisoneHypoglycemic AgentsInsulin ResistanceLuteinizing HormoneMetforminMetrorrhagiaMineralocorticoid Receptor AntagonistsOligomenorrheaPolycystic Ovary SyndromeSex Hormone-Binding GlobulinSpironolactoneTestosteroneTreatment OutcomeYoung Adult

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26370923

Citation

Diri, Halit, et al. "Comparison of Spironolactone and Spironolactone Plus Metformin in the Treatment of Polycystic Ovary Syndrome." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 32, no. 1, 2016, pp. 42-5.
Diri H, Karaburgu S, Acmaz B, et al. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2016;32(1):42-5.
Diri, H., Karaburgu, S., Acmaz, B., Unluhizarci, K., Tanriverdi, F., Karaca, Z., & Kelestimur, F. (2016). Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 32(1), 42-5. https://doi.org/10.3109/09513590.2015.1080679
Diri H, et al. Comparison of Spironolactone and Spironolactone Plus Metformin in the Treatment of Polycystic Ovary Syndrome. Gynecol Endocrinol. 2016;32(1):42-5. PubMed PMID: 26370923.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. AU - Diri,Halit, AU - Karaburgu,Sulbiye, AU - Acmaz,Banu, AU - Unluhizarci,Kursad, AU - Tanriverdi,Fatih, AU - Karaca,Zuleyha, AU - Kelestimur,Fahrettin, Y1 - 2015/09/15/ PY - 2015/9/16/entrez PY - 2015/9/16/pubmed PY - 2016/12/15/medline KW - Metformin KW - PCOS KW - spironolactone KW - treatment SP - 42 EP - 5 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 32 IS - 1 N2 - The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS). Thirty-seven patients with PCOS were randomly assigned to receive spironolactone 100 mg/d (spironolactone group, 18 patients) or spironolactone 100 mg/d plus metformin 2000 mg/d (combination group, 19 patients) for 12 months. BMI, modified Ferriman-Gallway score (FGS), serum levels of regarding hormones, and homeostasis model assessment of insulin resistance (HOMA-IR) index were assessed before and after the treatments. Six patients in the spironolactone group and four patients in the combination group reported inter-menstrual vaginal bleeding during treatments. In hirsutism scores, the spironolactone therapy resulted in 25.2% reduction, while combination therapy resulted in 28.3% reduction (p > 0.05, between groups). When the groups were compared in terms of percent changes in BMI, FGS, HOMA-IR, and hormone values other than free testosterone, no significant difference was noted. In the present study, FGSs were significantly decreased in both groups; however, combination therapy was not more effective than spironolactone alone in terms of BMI, FGS, hormone levels, or insulin resistance. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/26370923/Comparison_of_spironolactone_and_spironolactone_plus_metformin_in_the_treatment_of_polycystic_ovary_syndrome_ DB - PRIME DP - Unbound Medicine ER -